source
- Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdownAmgen has shared more data from a phase 3 Sjögren’s disease trial that dazzled analysts, digging into the details that could shape its showdown with Novartis.
- Bayer's Sunharbo becomes first FDA-approved factor XIa inhibitor blood thinnerBayer's oral anticoagulant Sunharbo, known as asundexian, has received FDA approval, making it the first factor XIa inhibitor cleared for use in the United States. The drug is intended to lower th…